GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » Cash per Share

Beyond Air (Beyond Air) Cash per Share : $0.88 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Beyond Air Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Beyond Air's Cash per Share for the quarter that ended in Dec. 2023 was $0.88.

Beyond Air Cash per Share Historical Data

The historical data trend for Beyond Air's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air Cash per Share Chart

Beyond Air Annual Data
Trend Jun15 Jun16 Dec17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cash per Share
Get a 7-Day Free Trial Premium Member Only 0.91 1.24 1.59 2.69 1.49

Beyond Air Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.77 1.49 1.80 1.21 0.88

Beyond Air Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Beyond Air's Cash per Share for the fiscal year that ended in Mar. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=45.882/30.74
=1.49

Beyond Air's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=31.263/35.48
=0.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beyond Air  (NAS:XAIR) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Beyond Air Cash per Share Related Terms

Thank you for viewing the detailed overview of Beyond Air's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Beyond Air (Beyond Air) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » Cash per Share
Comparable Companies
CATX IRME SGHT RTGN RBOT CTSO APYX CUTR NVNO NSPR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
48L:Germany
Address
900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530
Website
https://www.beyondair.net
Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Executives
Amir Avniel director, officer: President & CEO 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers officer: Chief Medical Officer C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Robert Carey director HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Michael A. Gaul officer: Chief Operating Officer 425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes director C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee director C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur director 750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Douglas Quinton Larson officer: Chief Financial Officer BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck officer: Chief Financial Officer C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman director 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv officer: Chief Financial Officer 2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635